

First author	Year	Publication type	No. randomised	Clinical condition(s)	Age	% -female	Interventions	
							Experimental	Control
Abdel-Hady	2011	Abstract	100	Heart failure, EF<35%	NR	NR	Ivabradine	Placebo
Abdel-Salam	2015	Paper	43	Dilated cardiomyopathy, EF<40%	50.8	46.5	Ivabradine	Placebo
Adamyan	2010	Abstract	118	Heart failure, EF>50%	58.0	24.8	Ivabradine	No intervention
Adamyan	2008	Abstract	145	Heart failure, EF<35%	58.0	30.0	Ivabradine	No intervention
Adamyan	2015	Abstract	104	Heart failure, EF>50%	63.2	NR	Ivabradine	No intervention
Al Saadi	2013	Abstract	NR	Stable ischemic heart failure	NR	NR	Ivabradine	No intervention
Arountunov	2008	Abstract	24	Decompensated heart failure	NR	NR	Ivabradine	No intervention
Babushkina	2020	Article	109	Heart failure, EF>50%	57.7	37	Ivabradine	No intervention
Bansal	2019	Abstract	309	Stable ischemic heart failure	NR	NR	Ivabradine	No intervention
Barilla	2016	Paper	58	Acute myocardial infarction, cardiogenic shock	55.4	32.8	Ivabradine	No intervention
Bi	2020	Paper	198	Heart failure	56.8	46.0	Ivabradine	No intervention
Cao	2019	Paper	82	Heart failure, EF<35%	69.3	50.0	Ivabradine	No intervention
Cavosoglu	2015	Paper	58	Decompensated heart failure, EF<35%	65.6	25.7	Ivabradine	No intervention
Chaudhari	2014	Abstract	158	Ischemic heart failure	NR	NR	Ivabradine	No intervention
Chen	2020	Paper	60	Chronic heart failure	62.5	35	Ivabradine	No intervention
Chen	2021	Paper	100	Chronic heart failure	57.8	42	Ivabradine	No intervention
Chen HX	2021	Paper	60	Severe chronic heart failure	70.5	45	Ivabradine	No intervention
Cheng	2017	Paper	90	Heart failure, EF<45%	71.0	44.4	Ivabradine	No intervention
Chumburidze	2013	Abstract	30	Dilated cardiomyopathy EF<35%	54.0	NR	Ivabradine	Placebo
Cong	2018	Paper	90	Heart failure	64.6	60.0	Ivabradine	No intervention
Deng	2017	Paper	82	Heart failure	61.8	40.2	Ivabradine	No intervention
Di	2020	Paper	126	Heart failure, EF<40%, HR>70	66.4	43.4	Ivabradine	No intervention
Fox (BEAUTIFUL)	2008	Paper	10917	Stable coronary artery disease, heart failure, EF<40%	65.2	17.1	Ivabradine	Placebo
Fu	2021	Paper	64	Chronic heart failure, EF 40-50%, HR>70	NR	NR	Ivabradine	No intervention
Gou	2017	Paper	60	Decompensated heart failure, EF<40%	63.7	48.3	Ivabradine	No intervention
Guo	2017	Paper	32	Heart failure, EF<40%	NR	0.0	Ivabradine	No intervention
He	2019	Paper	68	Coronary artery disease, heart failure, EF 40-49%	64.8	47.1	Ivabradine	No intervention
Hu	2017	Paper	60	Heart failure, EF<35%	68.0	45.0	Ivabradine	No intervention
Hu	2018	Paper	169	Acute myocardial infarction, heart failure	63.0	3.6	Ivabradine	No intervention
Huang J	2017	Paper	102	Heart failure	71.5	41.2	Ivabradine	No intervention
Komajda (EDIFY)	2017	Paper	179	Heart failure, EF>45%	72.5	64.8	Ivabradine	Placebo

Kosmala	2013	Paper	61	Heart failure, EF >50%	67.3	82.0	Ivabradine	Placebo
Li	2018	Paper	89	Heart failure	57.5	47.2	Ivabradine	No intervention
Li B	2020	Paper	110	Chronic heart failure, HR>100	64.2	35.4	Ivabradine	No intervention
Li Q	2020	Paper	96	Chronic heart failure, EF<50%, HR>75	65.3	33.6	Ivabradine	No intervention
Liu	2019	Paper	96	Heart failure	63.8	51.0	Ivabradine	No intervention
Liu	2020	Paper	98	Heart failure	67.4	60.2	Ivabradine	Placebo
Liu Y	2020	Paper	122	Heart failure, EF>50%, HR>70	65	34.4	Ivabradine	No intervention
Lofrano-Alves	2016	Paper	26	Heart failure, EF<40%	42.0	46.2	Ivabradine	Placebo
Lu	2019	Thesis	60	Dilated cardiomyopathy, EF<40%	47.2	43.3	Ivabradine	No intervention
Lu	2020	Paper	70	Chronic heart failure, EF 30-50%	69.9	34.3	Ivabradine	No intervention
Luo	2021	Paper	120	Heart failure, HR>70	84.2	42.5	Ivabradine	No intervention
Ma	2016	Thesis	60	Heart failure, EF<40%	NR	NR	Ivabradine	Placebo
Ma	2020	Paper	86	Heart failure	58.1	41.9	Ivabradine	Placebo
Mansour	2011	Paper	53	Dilated cardiomyopathy, EF<40%	49.0	40.0	Ivabradine	No intervention
Manz	2003	Paper	44	Cardiomyopathy, EF 20-50%	59.9	NR	Ivabradine	Placebo
Mao	2018	Paper	60	Heart failure	53.1	31.7	Ivabradine	No intervention
Masi de Luca	2018	Abstract	111	Heart failure, EF>50%	61.0	30.0	Ivabradine	Placebo
Moiseev	2011	Abstract	49	Heart failure, EF<40%	63.0	18.4	Ivabradine	No intervention
Nguyen	2018	Paper	19	Planned CABG, EF 20-40%	57.5	15.8	Ivabradine	Placebo
Ordu	2015	Paper	98	Heart failure, EF<35%	65.8	66.3	Ivabradine	No intervention
Pal	2015	Paper	22	Heart failure, EF>50%	74.6	65.0	Ivabradine	Placebo
Pan	2020	Paper	50	Decompensated heart failure, EF<40%	60.1	44.0	Ivabradine	No intervention
Potapenko	2011	Paper	49	Systolic, chronic heart failure	63.1	18.4	Ivabradine	No intervention
Qi	2019	Paper	96	Heart failure	59.7	45.8	Ivabradine	No intervention
Raja	2017	Paper	125	Dilated cardiomyopathy, EF<40%	47.2	43.1	Ivabradine	No intervention
Sallam	2016	Paper	100	Coronary artery disease, heart failure, EF<40%	63.5	30.0	Ivabradine	No intervention
Sarullo	2010	Paper	60	Stable, ischemic heart failure, EF<40%	52.7	25.0	Ivabradine	Placebo
Shen	2018	Paper	112	Heart failure	70.0	41.1	Ivabradine	No intervention
Sisakian	2015	Paper	54	Heart failure, EF<40%	59.9	18.5	Ivabradine	No intervention
Song	2021	Paper	96	Heart failure	69.4	43.8	Ivabradine	No intervention
Su	2020	Paper	70	Heart failure	69.0	44.3	Ivabradine	No intervention
Su D	2020	Paper	60	Chronic heart failure, EF<50%	61.8	48.3	Ivabradine	No intervention
Sun	2020	Paper	100	Heart failure	62.0	42.0	Ivabradine	No intervention

Sun	2021	Paper	118	Chronic heart failure	67.6	43.2	Ivabradine	No intervention
Swedberg (SHIFT)	2010	Paper	6558	Heart failure, EF<35%	60.4	23.4	Ivabradine	Placebo
Tang	2018	Paper	62	Heart failure, EF<40%	63.2	29.0	Ivabradine	No intervention
Tarlovskaya	2011	Abstract	18	Heart failure, EF<35%	53.5	NR	Ivabradine	Placebo
Tatarchenko	2008	Paper	59	Coronary artery disease, heart failure, EF>45%	57.3	NR	Ivabradine	No intervention
Tsutsui	2019	Paper	254	Heart failure, EF<35%	60.7	18.0	Ivabradine	Placebo
Tsutsui	2016	Paper	125	Heart failure, EF<35%	59.0	14.3	Ivabradine	Placebo
Tumasyan	2009	Abstract	126	Severe heart failure	NR	NR	Ivabradine	No intervention
Tumasyan	2012	Abstract	76	Heart failure	57.4	NR	Ivabradine	No intervention
Tumasyan	2016	Abstract	210	Severe heart failure	57.4	NR	Ivabradine	No intervention
Tumasyan	2017	Abstract	110	Heart failure	63.2	NR	Ivabradine	No intervention
Tumasyan	2018	Abstract	91	Heart failure, mid range EF	50.1	NR	Ivabradine	No intervention
Vatinian	2015	Abstract	52	Coronary artery disease, heart failure, EF<35%	NR	NR	Ivabradine	No intervention
Wang	2019	Paper	68	Heart failure, EF <35%	55.8	0.5	Ivabradine	No intervention
Wang FC	2017	Paper	96	Heart failure	70.6	43.8	Ivabradine	No intervention
Wang JJ	2017	Paper	40	Heart failure	52.9	55.0	Ivabradine	No intervention
Wang Q	2017	Paper	120	Heart failure	62.3	35.0	Ivabradine	No intervention
Wang RM	2017	Paper	78	Heart failure	59.9	28.3	Ivabradine	No intervention
Wang YH	2018	Paper	68	Heart failure	66.0	42.3	Ivabradine	No intervention
Wang GK	2020	Paper	72	Chronic heart failure	68.5	48.6	Ivabradine	No intervention
Wang LJ	2020	Paper	70	Chronic heart failure	57.0	22.9	Ivabradine	No intervention
Wei	2019	Paper	64	Heart failure, EF<45%	60.6	39.7	Ivabradine	No intervention
Xia	2016	Paper	78	Heart failure	60.7	44.9	Ivabradine	No intervention
Xing	2018	Paper	20	Heart failure	52.7	55.0	Ivabradine	No intervention
Xu	2019	Paper	77	Heart failure, EF<50%	68.1	0.5	Ivabradine	No intervention
Xu	2020	Paper	122	Heart failure, EF<45%	71.0	56.6	Ivabradine	No intervention
Xue	2020	Paper	90	Chronic heart failure	59.2	45.6	Ivabradine	No intervention
Yang WT	2019	Paper	80	Heart failure, EF<45%	62.2	0.4	Ivabradine	No intervention
Yang Z	2019	Paper	135	Heart failure	65.7	0.3	Ivabradine	No intervention
Yao	2016	Paper	72	Heart failure, EF<40%	NR	NR	Ivabradine	No intervention
Yi	2017	Paper	90	Heart failure, EF<45%	66.6	32.2	Ivabradine	Placebo
Yu	2019	Paper	66	Dilated cardiomyopathy, EF<40%	46.8	0.4	Ivabradine	No intervention
Yu	2018	Paper	86	Heart failure	62.5	43.0	Ivabradine	No intervention

Yue	2016	Thesis	80	Heart failure, EF<40%	68.3	50.0	Ivabradine	No intervention
Zeng FC	2019	Paper	65	Heart failure	72.0	0.6	Ivabradine	No intervention
Zeng XM	2019	Paper	90	Heart failure	70.6	0.5	Ivabradine	No intervention
Zhang	2018	Paper	60	Coronary artery disease, heart failure	64.2	48.3	Ivabradine	No intervention
Zhang J	2019	Paper	86	Heart failure	66.2	0.5	Ivabradine	No intervention
Zhang XJ	2019	Paper	110	Heart failure	61.6	0.4	Ivabradine	No intervention
Zhang	2020	Paper	85	Coronary heart disease, heart failure	64.4	0.4	Ivabradine	No intervention
Zhang Y	2020	Paper	54	Chronic heart failure	NR	51.9	Ivabradine	No intervention
Zhang	2021	Paper	94	Chronic heart failure	70.9	44.7	Ivabradine	No intervention
Zhao	2020	Paper	80	Chronic heart failure	68.3	46.3	Ivabradine	No intervention
Zhou	2019	Thesis	60	Heart failure	54.8	0.4	Ivabradine	No intervention
Zhou	2020	Paper	86	Heart failure, EF<35%, HR>100	65	47.7	Ivabradine	No intervention